Intech Investment Management LLC Acquires 62,963 Shares of Glaukos Corporation $GKOS

Key Points

• Intech Investment Management LLC significantly increased its holdings in Glaukos Corporation by 212.7%, acquiring an additional 62,963 shares in the first quarter, bringing its total ownership to 92,564 shares valued at approximately $9.11 million.
• Glaukos reported a revenue increase of 29.7% year-over-year, with earnings per share beating analyst expectations at ($0.24) compared to a forecast of ($0.26).
• Analysts currently have a consensus rating of "Moderate Buy" for Glaukos, with an average price target of $124.83, reflecting optimism despite some recent ratings downgrades.

Intech Investment Management LLC raised its position in Glaukos Corporation (NYSE:GKOS - Free Report) by 212.7% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 92,564 shares of the medical instruments supplier's stock after acquiring an additional 62,963 shares during the period. Intech Investment Management LLC owned about 0.16% of Glaukos worth $9,110,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of GKOS. Bessemer Group Inc. lifted its holdings in Glaukos by 133.9% during the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock worth $27,000 after acquiring an additional 158 shares in the last quarter. Whipplewood Advisors LLC boosted its position in Glaukos by 3,957.1% during the first quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock valued at $28,000 after acquiring an additional 277 shares during the last quarter. First Horizon Advisors Inc. boosted its position in shares of Glaukos by 72.9% during the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock worth $37,000 after purchasing an additional 159 shares in the last quarter. Versant Capital Management Inc increased its stake in Glaukos by 583.9% in the 1st quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock valued at $38,000 after buying an additional 327 shares during the last quarter. Finally, Forum Financial Management LP purchased a new stake in shares of Glaukos during the 4th quarter worth approximately $211,000. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Price Performance

Shares of GKOS traded up $1.41 during trading hours on Tuesday, reaching $82.05. The company had a trading volume of 381,395 shares, compared to its average volume of 929,324. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. The firm has a 50 day simple moving average of $93.06 and a 200-day simple moving average of $95.22. Glaukos Corporation has a 12-month low of $77.10 and a 12-month high of $163.71. The company has a market capitalization of $4.71 billion, a price-to-earnings ratio of -49.76 and a beta of 0.77.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.02. The company had revenue of $124.12 million for the quarter, compared to analysts' expectations of $115.49 million. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The firm's revenue for the quarter was up 29.7% compared to the same quarter last year. During the same period last year, the company earned ($0.52) EPS. Glaukos has set its FY 2025 guidance at EPS. Research analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current year.

Wall Street Analyst Weigh In

GKOS has been the subject of several recent research reports. BTIG Research reissued a "buy" rating and issued a $118.00 price target on shares of Glaukos in a research note on Wednesday, September 10th. Mizuho set a $130.00 price target on shares of Glaukos in a report on Thursday, July 31st. William Blair upgraded shares of Glaukos to a "strong-buy" rating in a research report on Thursday, July 31st. Zacks Research cut shares of Glaukos from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 15th. Finally, Wells Fargo & Company upped their price target on shares of Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $124.83.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.